Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$149.07
-0.5%
$155.55
$91.86
$230.02
$7.34B1.48961,128 shs663,865 shs
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$65.94
+0.1%
$71.07
$60.56
$82.49
$8.00B0.812.18 million shs1.93 million shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$31.33
$31.33
$19.45
$31.79
$2.77B0.731.30 million shsN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$48.02
-0.7%
$48.02
$37.63
$51.88
$10.67B0.641.64 million shs1.29 million shs
10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.00%-10.68%-6.70%+4.20%-25.82%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.00%-3.00%-10.19%-6.43%-4.35%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.00%0.00%0.00%0.00%+28.56%
Qiagen N.V. stock logo
QGEN
Qiagen
0.00%-3.77%-0.23%+11.87%+8.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.6464 of 5 stars
3.14.00.04.72.72.51.9
Henry Schein, Inc. stock logo
HSIC
Henry Schein
4.0953 of 5 stars
3.22.00.03.42.41.71.9
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.7265 of 5 stars
1.00.02.51.70.01.72.5
Qiagen N.V. stock logo
QGEN
Qiagen
3.5568 of 5 stars
1.12.01.74.52.71.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.27
Hold$175.6917.86% Upside
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.33
Hold$75.5814.62% Upside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.09
Hold$26.57-15.19% Downside
Qiagen N.V. stock logo
QGEN
Qiagen
2.27
Hold$49.693.47% Upside

Current Analyst Ratings Breakdown

Latest HSIC, PDCO, QGEN, and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$180.00 ➝ $190.00
8/7/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/7/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$145.00 ➝ $160.00
8/7/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$155.00 ➝ $165.00
8/7/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$80.00 ➝ $76.00
8/7/2025
Qiagen N.V. stock logo
QGEN
Qiagen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.00
8/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$75.00 ➝ $70.00
8/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$78.00 ➝ $70.00
8/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$86.00 ➝ $78.00
7/25/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$80.00 ➝ $75.00
7/14/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$75.00
(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.81$21.76 per share6.85$67.80 per share2.20
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.67B0.63$7.33 per share9.00$32.33 per share2.04
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.51B0.43$3.42 per share9.17$11.18 per share2.80
Qiagen N.V. stock logo
QGEN
Qiagen
$1.98B5.40$3.20 per share14.99$16.05 per share2.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$22.20M-$1.33N/A13.554.74-1.69%15.74%7.09%N/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$390M$3.1021.2713.142.173.05%14.36%5.52%N/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$185.93M$1.5418.3212.842.712.37%19.77%6.66%8/26/2025 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$1.6928.3719.522.4518.30%14.77%8.87%N/A

Latest HSIC, PDCO, QGEN, and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.50$3.12+$0.62$1.06$983.76 million$1.03 billion
8/5/2025Q2 2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.19$1.10-$0.09$0.70$3.22 billion$3.24 billion
8/5/2025Q2 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60$0.60N/A$0.44$523.97 million$533.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.043.32%N/A67.53%N/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%N/A14.79%N/A

Latest HSIC, PDCO, QGEN, and CRL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%7/2/20257/3/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.69
1.36
1.16
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.51
1.41
0.75
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.34
1.37
0.76
Qiagen N.V. stock logo
QGEN
Qiagen
0.40
3.37
2.83

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
85.43%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
20,10049.21 million48.57 millionOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000121.27 million119.89 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,70088.47 million86.64 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,765222.29 million202.29 millionOptionable

Recent News About These Companies

William Blair Has Optimistic Outlook of Qiagen Q1 Earnings
Qiagen (NYSE:QGEN) Issues FY 2025 Earnings Guidance
Qiagen (NYSE:QGEN) Issues Q3 2025 Earnings Guidance
Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript
A Look at Qiagen's Upcoming Earnings Report
Qiagen (QGEN) Matches Q2 Earnings Estimates
Wall Street Zen Upgrades Qiagen (NYSE:QGEN) to Strong-Buy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$149.07 -0.71 (-0.47%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$150.82 +1.75 (+1.18%)
As of 08/8/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Henry Schein stock logo

Henry Schein NASDAQ:HSIC

$65.94 +0.04 (+0.06%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$65.94 +0.00 (+0.01%)
As of 08/8/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Patterson Companies stock logo

Patterson Companies NASDAQ:PDCO

Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.

Qiagen stock logo

Qiagen NYSE:QGEN

$48.02 -0.34 (-0.70%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$48.00 -0.02 (-0.03%)
As of 08/8/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.